SEC Form 4 · accession 0001140361-17-019037
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Apr 28, 2017
Accepted (ET)
May 9, 2017 · 1:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 28, 2017 | A | 302 | $70.304 | A | 238,496 | D | |
| Common StockF2 | May 5, 2017 | M | 5,000 | $17.33 | A | 243,496 | D | |
| Common StockF2,F3 | May 5, 2017 | S | 5,000 | $99.00 | D | 238,496 | D | |
| Common StockF2 | May 8, 2017 | M | 5,000 | $17.33 | A | 243,496 | D | |
| Common StockF2,F3 | May 8, 2017 | S | 5,000 | $93.17 | D | 238,496 | D | |
| Common Stock | holding | — | — | — | 182,801 | I | Shares held by Jean-Jacques Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F2,F4 | $17.33 | May 5, 2017 | M | 5,000 | D | Dec 7, 2007 | Jun 6, 2017 | Common Stock | 5,000 | 42,423 | D |
| Stock Option (Right to buy Common Stock)F2,F4 | $17.33 | May 8, 2017 | M | 5,000 | D | Dec 7, 2007 | Jun 6, 2017 | Common Stock | 5,000 | 37,423 | D |
Explanation of responses
- F1Represents shares acquired by the reporting person pursuant to the issuer's Employee Stock Purchase Plan
- F2Trade made pursuant to a 10b5-1 plan executed on November 15, 2016
- F3All shares sold at the same price.
- F4Reflects the number of stock options outstanding after the transaction from this specific stock option grant.